These findings suggest that type‐2 and PDE4 overexpression in COPD patients with higher sputum eosinophil counts contribute to the differential clinical response to PDE4i observed in previous clinical trials. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.